3rd Quarter 2019 Quarterly Disclosure 13 November 2019 Marie - - PowerPoint PPT Presentation

▶
3rd quarter 2019
SMART_READER_LITE
LIVE PREVIEW

3rd Quarter 2019 Quarterly Disclosure 13 November 2019 Marie - - PowerPoint PPT Presentation

Apr 29, 2023 362 likes •723 views

3rd Quarter 2019 Quarterly Disclosure 13 November 2019 Marie Roediger CFO 1 Gl Glob obally ally Po Positi sition oned ed for for 25 25 yea years rs Ni Nich che Play Player i er in Isoto n Isotope pe M Mark arket et Cancer

slide-1
SLIDE 1

1

3rd Quarter 2019

Quarterly Disclosure 13 November 2019 Marie Roediger CFO

slide-2
SLIDE 2

2

Berlin

Gl Glob

  • bally

ally Po Positi sition

  • ned

ed for for 25 25 yea years rs Ni Nich che Play Player i er in Isoto n Isotope pe M Mark arket et

Geräte

Rohstoffe/ API Rohstoffe/ API

LDR LDR HDR

Raw materials API Projects/ API

Pharmaceuticals (RADIOPHARMA)

Synthesis Devices

EUR 80 Mio. 59% EUR 20 Mio. 16% EUR 33 Mio. 25%

Strong 3rd Half Year 2019 with Revenues of € 133 Mio. (FY 2018: € 169 Mio.)

Industrial Components (ISOTOPE PRODUCTS)

Production Services Trading Disposal

Cancer Radiation

(RADIATION THERAPY)

Implants Applicators Devices

Slides for Illustration – The spoken word shall be binding

slide-3
SLIDE 3

3

Fro From Ja Janu nuary ary 1st 20 1st 2020 20: Med Medical Seg ical Segmen ment t Po Pool

  • l

Geräte

Rohstoffe/ API Rohstoffe/ API

LDR LDR HDR

Raw materials API Projects/ API

Pharmaceuticals (RADIOPHARMA)

Synthesis Devices

Industrial Components (ISOTOPE PRODUCTS)

Production Services Trading Disposal

Cancer Radiation

(RADIATION THERAPY)

Implants Applicators Devices

From 1.1.2020: MEDICAL

Slides for Illustration – The spoken word shall be binding

Engineering

slide-4
SLIDE 4

800 800 Employ Employee ees (Head (Headco coun unts ts) ) 19 19 Site Sites s Wo World rldwide wide

4

Result Q3-2019

(Mio. EUR)

Revenues 133,2 Net Income 18,8

2%

2 44% 41% 9% 6% EUROPE AMERICA ASIA MIDDLE EAST & AFRICA

Slides for Illustration – The spoken word shall be binding

slide-5
SLIDE 5

Rev Reven enue ues of

  • f about

about € 170 Mio.

  • Mio. in

in 2018 2018

in Mio. EUR

5

  • Incl. discontinued and continued operations

18% organic growth in 2018

0,13 1 2 4 6 6 8 10 24 33 31 29 36 42 50 54 71 101 111 116 120 117 127 140 138 145 169 20 40 60 80 100 120 140 160 180 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

Slides for Illustration – The spoken word shall be binding

slide-6
SLIDE 6

Rev Reven enue ues pe per r Seg Segmen ment

Q3 Q3-2019 2019 vs vs. . Q3 Q3-2018 2018, Mio. Euro

6

Total Revenues of 133,2 Mio. EUR in Q3-2019 (Q3-2018: Euro 123,8 Mio.) An increase of 8% in Q3-2019

Slides for Illustration – The spoken word shall be binding

slide-7
SLIDE 7

Rev Reven enue ue Gro Growth wth all S

all Seg egmen ments ts Q3 Q3-20 2019 19, , in Mio. Euro

7 Slides for Illustration – The spoken word shall be binding

slide-8
SLIDE 8

Isot Isotop

  • pe

e Pro Produ duct cts s Reve

Revenu nue e Gr Growth

  • wth

Q3 Q3-20 2019 19, , in Mio. EUR

8 Slides for Illustration – The spoken word shall be binding

slide-9
SLIDE 9

Rad Radioph iophar arma ma Reve

Revenu nue Gr e Growth

  • wth

Q3 Q3-20 2019 19, , in Mio. EUR

9

Pharmazeutische Radioisotope

Slides for Illustration – Only the spoken word shall be binding

slide-10
SLIDE 10

Rad Radiation iation The Thera rapy py Reve

Revenu nue e Gr Growth

  • wth

Q3 Q3-20 2019 19, , in Mio. EUR

10 Slides for Illustration – The spoken word shall be binding

slide-11
SLIDE 11

11

Q3-2019

Net Income

(Earnings after tax and minorities)

Distribution and Growth

Slides for Illustration – The spoken word shall be binding

slide-12
SLIDE 12

Net Net Inco Income me Q3 Q3-20 2019 19 vs vs. . Q3 Q3-20 2018 18, , in Mio. EUR

12

Net Income of 18,8 Mio. EUR in Q3-2019 vs. 13,0 Mio. in Q3-2018

Slides for Illustration – The spoken word shall be binding

slide-13
SLIDE 13

Net In Net Inco come me and and Sa Sales les Di Distribution stribution pe per Se r Segm gmen ent t in Q3 in Q3-2019 2019

13

Net income of 18,8 Mio. EUR Sales of 132,2 Mio. EUR

44% 3% 53% 60% 15% 25%

Slides for Illustration – The spoken word shall be binding

slide-14
SLIDE 14

Net Net Inco Income me Gro Growth wth all all Seg Segmen ments ts in Q3 in Q3-20 2019 19, , in Mio. EUR

14 Slides for Illustration – The spoken word shall be binding

slide-15
SLIDE 15

15

Q3-2019 Cashflow and Balance Sheet

Slides for Illustration – The spoken word shall be binding

slide-16
SLIDE 16

Balan Balance ce She Sheet et

as as of

  • f 30

30.09.20 .09.2019 19, , in Mio. EUR

16

  • Cash and cash equivalents at period end of 71 Mio. EUR
  • Debt Free (except accounted leasing according to IFRS 16)
  • Equity Ratio of 53%

Cash 71 Equity 131 Recievables 25 Minority Interests 6 Inventory 31 Loans 18 Intangible Assets 70 Accruals/Provisions 66 Fixed Assets 38 Other Short Term Payables 31 Others 25 Other Long Term Payables 6 Total Activ 259 Total Passiv 259

Slides for Illustration – The spoken word shall be binding

slide-17
SLIDE 17

Cashflow Cashflow in in Q3

Q3-20 2019 19, , in Mio. EUR

17

EBITDA of 36,6 Mio. EUR

Slides for Illustration – The spoken word shall be binding

slide-18
SLIDE 18

Net Net Liqu Liquidity idity in in Q3 Q3-2019, 2019,

in Mio. EUR

18

+10 mm EUR for treasury shares

Slides for Illustration – The spoken word shall be binding

2014 2015 2016 2017 2018 Q3-2019 Liquidity 22 31 37 58 54 71 Debt 19 16 12 2 Net Liquidity 3 15 25 56 54 71 10 20 30 40 50 60 70 80 10 20 30 40 50 60 70 80 In Mio. EUR

slide-19
SLIDE 19

Sha Share re Per Performa formanc nce e and and Dividen Dividend d in in EUR/Share EUR/Share

19

0,60 0,60 0,60 0,66 0,8 1,2

0,50 0,60 0,70 0,80 0,90 1,00 1,10 1,20 20 40 60 80 100 120 140 160 180 2014 2015 2016 2017 2018 2019

Dividende in EUR / Aktie EUR/Aktie

Slides for Illustration – The spoken word shall be binding

slide-20
SLIDE 20

Str Strat ateg egy / Gr / Growt

  • wth

h Opp Oppor

  • rtu

tunities nities

20

From tigers, dragons and other animals

slide-21
SLIDE 21

Since Since 2014 2014 Incr Increa easing sing M&A M&A Act Activities ivities

  • Bayer/ ALGETA

– (2014)

  • IPSEN/ OPS

– 2015

  • NOVARTIS/ AAA

– (2017)

  • NOVARTIS/ Endocyte

– 2017

  • GCP/ SIRTEX

– June 2018

  • Boston Scientific/ BTG

– November 2018

  • Bracco/ Blue Earth

– April 2019

2,1 Mrd. USD 2,1 Mrd. USD 4,0 Mrd. USD 0,1 Mrd. USD

Ra-223 Lu-177

1,4 Mrd. USD

Ge-68 Y-90 Ge-68 Y-90

4,2 Mrd. USD 0,5 Mrd. EUR

F-18 Isotop

Slides for Illustration – The spoken word shall be binding

slide-22
SLIDE 22

EANM EANM Con Confi firms rms: : No No End End to to M&A M&A Act Activities ivities

  • Bayer/ ALGETA

– (2014)

  • IPSEN/ OPS

– 2015

  • NOVARTIS/ AAA

– (2017)

  • NOVARTIS/ Endocyte

– 2017

  • GCP/ SIRTEX

– Juni 2018

  • Boston Scientific/ BTG

– November 2018

  • Bracco/ Blue Earth

– April 2019

2,1 Mrd. USD 2,1 Mrd. USD 4,0 Mrd. USD 0,1 Mrd. USD

Ra-223 Lu-177

1,4 Mrd. USD

Ge-68 Y-90 Ge-68 Y-90

4,2 Mrd. USD 0,5 Mrd. EUR

F-18 Isotop

Slides for Illustration – The spoken word shall be binding

slide-23
SLIDE 23

Sev Sever eral al Tre Trend nds s co come me together together

  • 1. Precision Oncology

– Germanium-68 for Diagnosis – Lutetium-177 for Therapy

  • 2. China

– Liver carcinoma = high priority in health policy – Boom of Yttrium-90 providers for radioembolisation products (SIRTEX, BTG, providers of generics)

  • 3. Swallows/ e.g. Alpha-Emitter

– BAYER = forerunner – Encouraging investment rounds

23

A tiger by the tail The Dragon The Swallow

Slides for Illustration – The spoken word shall be binding

slide-24
SLIDE 24

Pre Precision cision Onc Oncolog

  • logy,

, st stil ill l at at the the beginning beginning

Advantages

  • Therapy only for patients

who respond to the diagnostic

– avoids unnecessary expenses – avoids unnecessary patient stress

  • Strengthens nuclear

physicians as a distribution channel

24

Neuroendocrine tumors Prostate, Renal cancer Non-Hodgkin-Lymphoma Gastro THERAPY (Lu-177) DIAGNOSIS (Ge-68)

Slides for Illustration – The spoken word shall be binding

slide-25
SLIDE 25

Exp Expan ansion sion of

  • f Indica

Indication tion is is li like kely ly to to come come

25

https://clinicaltrials.gov/ct2/results?term=lutetium&age_v=&gndr=&type=&rslt=&phase=1&phase=2&Search=Apply

Clinical studies with Lu-177 acc. to FDA, Phase II or higher, as of May 2019

Slides for Illustration – The spoken word shall be binding

slide-26
SLIDE 26

EZA EZAG G well well pos positioned itioned in in the the diag diagno nosis sis (Ge (Ge-68) 68)

  • Generators
  • Synthesis modules
  • Work benches
  • Complete isotope production

26

Therapeutic arm (Lutetium) is also making progress:

  • Technology validated
  • Supply chain established
  • First deliveries to customers

have been made

Slides for Illustration – The spoken word shall be binding

slide-27
SLIDE 27

YTTR YTTRIUM IUM-90 90

27

The Chinese Health Market is growing

Slides for Illustration – The spoken word shall be binding

slide-28
SLIDE 28

What‘s Dr Driving iving the the Dr Drag agon

  • n?

? Reimbu Reimburs rseme ement nt and and Liver Liver Can Cance cer

28

Age-standardized incidence rates of hepatocellular carcinoma per 100,000 populations at risk, in different regions of world (Source: GLOBOCAN 2002).

China 280,000 men 100,000 women ~380,000 cases per year (!)

Reimbursement China ~ 11,000 US$/ patient

Slides for Illustration – The spoken word shall be binding

slide-29
SLIDE 29

Par Part t of a

  • f a La

Larg rger er Political Political Pro Progr gram am Hea Health lth Car Care e Refo Reform rm

Middle class has grown large, wealthy, and old.

29

Various Political Impulses

  • Reimbursement System and National

Insurance established

  • Medical free trade zone Hainan island as

showcase and laboratory for private health care provider

  • Privileged access for Chinese manufacturers
  • High Tech segment on Shanghai Stock

Exchange

Slides for Illustration – The spoken word shall be binding

slide-30
SLIDE 30
  • EZR is the world’s largest manufacturer of industrial Sr-90 sources and has excellently

assured Sr-90 feedstock supplies

  • Own Sr-90 purification process of feedstock Sr-90
  • Robust Y-90 generator technology with 5 TBq (150 Ci) generators that can be added to meet

demand

  • Weekly production for customers worldwide
  • Marketing Authorisation in the Europe for Yttriga
  • Drug Master File with FDA/ GMP grade radiopharmaceuticals
  • Sufficient capacity for expansion

Po Pole le Po Positio sition n for for EZAG EZAG

Slides for Illustration – Only the spoken word shall be binding

slide-31
SLIDE 31

EZAG EZAG is is inves investing ting

31

USA (in planning phase) Germany China/ Chengdu Global network of redundant production facilities

Slides for Illustration – The spoken word shall be binding

slide-32
SLIDE 32

Fina Financ ncial ial Calen Calenda dar / I / IR-Con Conta tact ct

ISIN DE0005659700 Reuters EUZ.DE

32

26.11.2019 German Equity Forum in Frankfurt 31.03.2020 Publication FY2019 Report 12.05.2020 Quarterly Report I 17.06.2020 Annual General Meeting in Berlin 13.08.2020 Quarterly Report II 10.11.2020 Quarterly Report III Eckert & Ziegler AG Karolin Riehle Investor Relations & PR Robert-Rössle-Str. 10 D-13125 Berlin

  • Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.com

Slides for Illustration – The spoken word shall be binding

slide-33
SLIDE 33

Thank Thank you you!

33 Slides for Illustration – The spoken word shall be binding